VJHemOnc Podcast
Highlights from ISA 2024: the importance of early diagnosis in AL amyloidosis, trials in progress & patient selection for SCT
Jun 25, 2024
Experts Mario Nuvolone, Vaishali Sanchorawala, and Patrick Hagen discuss the critical importance of early diagnosis in AL amyloidosis, ongoing clinical trials like Venetoclax and Exazomib, patient selection for SCT, and challenges in managing relapsed refractory amyloidosis.
08:43
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Early diagnosis crucial in AL amyloidosis for better treatment outcomes and reduced morbidity.
- Multiple clinical trials ongoing to address treatment questions, including new approaches for relapsed cases.
Deep dives
Importance of Early Diagnosis in Amyloidosis
Early diagnosis in amyloidosis is crucial as identifying the disease before advanced organ damage occurs significantly impacts treatment options and reduces morbidity. Patients with a non-monoclonal gamma apathy under hematologic follow-up should also be evaluated for potential progression towards amyloidosis. Screening for early organ involvement through biomarkers allows for presymptomatic detection and successful treatment outcomes.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
